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ABSTRACT
Angiogenesis plays a key role in various physiological and pathological conditions, 
including inflammation and tumor growth. The bone morphogenetic protein (BMP) 
antagonist gremlin has been identified as a novel pro-angiogenic factor. Gremlin 
promotes neovascular responses via a BMP-independent activation of the vascular 
endothelial growth factor (VEGF) receptor-2 (VEGFR2). BMP antagonists may act 
as covalent or non-covalent homodimers or in a monomeric form, while VEGFRs 
ligands are usually dimeric. However, the oligomeric state of gremlin and its role in 
modulating the biological activity of the protein remain to be elucidated.
Here we show that gremlin is expressed in vitro and in vivo both as a monomer 
and as a covalently linked homodimer. Mutagenesis of amino acid residue Cys141 
prevents gremlin dimerization leading to the formation of gremlinC141A monomers. 
GremlinC141A monomer retains a BMP antagonist activity similar to the wild-type 
dimer, but is devoid of a significant angiogenic capacity. Notably, we found that 
gremlinC141A mutant engages VEGFR2 in a non-productive manner, thus acting as 
receptor antagonist. Accordingly, both gremlinC141A and wild-type monomers inhibit 
angiogenesis driven by dimeric gremlin or VEGF-A165. Moreover, by acting as a VEGFR2 
antagonist, gremlinC141A inhibits the angiogenic and tumorigenic potential of murine 
breast and prostate cancer cells in vivo.
In conclusion, our data show that gremlin exists in multiple forms endowed with 
specific bioactivities and provide new insights into the molecular bases of gremlin 
dimerization. Furthermore, we propose gremlin monomer as a new inhibitor of VEGFR2 
signalling during tumor growth.
INTRODUCTION
The transforming growth factor-β (TGF-β) 
superfamily comprises over thirty cystine-knot 
secreted proteins, including the members of the bone 
morphogenetic protein (BMP) family. They transduce 
a variety of cellular responses through the assembly of 
heterodimeric serine/threonine kinase receptors, leading 
to the activation of smad transcription factors [1]. BMPs 
are aberrantly expressed in multiple malignancies, 
where they elicit context-dependent effects that can be 
both detrimental and beneficial for tumor growth and 
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progression [2, 3]. The activity of BMPs is inhibited by 
various extracellular antagonists that hamper the binding 
of BMPs to their receptors, including chordin, noggin, 
follistatin and the DAN (differential screening selected 
gene aberrative in neuroblastoma) family of BMP 
antagonists [4–6].
Gremlin is a multifunctional protein belonging to 
the DAN family of BMP antagonists. It plays essential 
roles during embryonic development [7–9] and in the 
pathogenesis of several human diseases, such as fibrosis 
[10] and cancer [11, 12], where it can promote epithelial-
to-mesenchymal transition (EMT) [13] by inhibiting BMP-
2, BMP-4 and BMP-7. Also, gremlin, once released by 
tumor cells, stimulates neovascular and pro-inflammatory 
responses in a BMP-independent manner [14] due to its 
capacity to bind and activate vascular endothelial growth 
factor (VEGF) receptor-2 (VEGFR2), the main transducer 
of VEGF-mediated angiogenic signals [15–17], and 
to bind heparan-sulphate proteoglycans (HSPGs) [18, 
19] on endothelial cells (ECs). Interestingly, gremlin is 
overexpressed in several human cancers [12], where it 
may neutralize the negative regulatory role of BMPs on 
cell proliferation, modulate EMT [13], and enhance tumor 
growth by stimulating tumor angiogenesis [14, 15] and 
inflammation [16].
Beside gremlin, DAN family includes, among others, 
DAN, cerberus, protein related to DAN and cerberus 
(PRDC), uterine sensitization-associated gene 1, and 
sclerostin (SOST). They are small glycosylated proteins 
characterized by a core ‘DAN’ domain that contains a 
cystine-knot motif responsible for BMP binding, as shown 
by NMR analysis of SOST [20]. This suggests that the 
structure of DAN family members may resemble that 
of TGF-β superfamily growth factors. Relevant to this 
point, several TGF-β family members have an unpaired 
cysteine residue that forms an intermolecular disulphide 
bridge holding together two monomers and leading to 
the formation of covalent homo or heterodimers [21]. 
At variance, PRDC forms highly stable non-covalent 
homodimers [22] whereas SOST exists as a monomer [20].
Gremlin structure has not been solved yet, however, 
sequence alignments [21] and homology structural 
modelling based on human chorionic gonadotropin [23] 
and SOST [20] predicted that gremlin may form covalent 
homodimers through Cys141. Recently it has been reported 
that gremlin may form homodimers [19], but experimental 
evidences are not available to unambiguously unravel the 
oligomerization state of gremlin and to correlate it with the 
biological activities of the protein.
Here we show that gremlin exists both in a 
monomeric form and as a covalent homodimer held 
together by Cys141. To understand how gremlin 
oligomerization affects its biological activity, we 
compared wild-type gremlin (gremlinWT) dimers with a 
monomeric gremlin mutant where Cys141 was mutated 
to alanine (gremlinC141A). Analysis of the biological 
activity of gremlinC141A demonstrates for the first time that 
monomeric gremlin, while retaining its BMP-antagonist 
activity, is devoid of a significant angiogenic capacity due 
to its non-productive binding to VEGFR2. Eventually, 
gremlin monomer acts as a VEGFR2 antagonist, inhibiting 
the angiogenic activity of dimeric gremlinWT and VEGF-A, 
and reducing tumor growth and vascularization. In 
conclusion, our data demonstrate that monomeric gremlin 
acts as a potent antagonist of VEGFR2, with potential 
implications in VEGFR2-related physiological and 
pathological processes, including cancer.
RESULTS
Gremlin exists both as a monomer and as a 
homodimer
Gremlin immunoprecipitated from the lysates 
of murine organs and analysed by SDS-PAGE under 
reducing conditions migrates as immunoreactive 20-24 
kDa bands (data not shown), as anticipated for the non-
glycosylated and N-glycosylated forms of the protein 
monomer, respectively [24]. In contrast, when analysed 
by SDS-PAGE under non-reducing conditions, gremlin 
is detectable as 20-24 kDa monomers as well as 40-44 
kDa immunoreactive bands (Figure 1A), consistent with 
in silico studies predicting gremlin to form covalent 
homodimers [21, 23]. In the different tissues, the 
monomer/dimer ratio ranged between 0.8 and 0.5, as 
assessed by densitometric analysis of the immunoreactive 
bands. FGF2-transformed murine aortic endothelial cells 
(FGF2-T-MAE) express gremlin [14] that is released 
both in monomeric and dimeric forms in the cell culture 
medium (Figure 1B). In order to understand whether the 
cellular redox state may affect the gremlin monomer/dimer 
equilibrium, FGF2-T-MAE cells were treated with H2O2 
and the oligomeric state of gremlin was analyzed under 
non-reducing conditions. As shown in Figure 1B, H2O2 
treatment induced a dose-dependent increase in the dimer-
to-monomer ratio of the released protein, confirming that 
gremlin may exist in a redox-dependent monomer/dimer 
equilibrium.
On these bases, his-tagged wild-type gremlin 
(gremlinWT) was expressed in HEK293T cells and 
purified from the cell supernatant by immobilized metal 
affinity chromatography (IMAC). Similar to endogenous 
gremlin, recombinant gremlin is produced and released 
both in monomeric and dimeric forms (Figure 1C). Size 
exclusion chromatography demonstrated that IMAC 
purified gremlinWT elutes in three major peaks with 
relative retention volumes equal to 7.7, 8.0 and 8.3 mL, 
consistent with an apparent molecular weight equal 
to ≈48.3 kDa (dimeric form), ≈25.5 kDa (monomeric 
form) and ≈13.4 kDa [representing a gremlin breakdown 
product [25]], respectively (Figure 1D). Thus, gremlin 
exists in monomeric and dimeric state also under native 
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conditions. In addition, when IMAC purified gremlinWT 
was further subjected to heparin-affinity chromatography, 
gremlin dimer eluted from the heparin column at higher 
ionic strength than the monomer (Figure 1E). On this 
basis, recombinant gremlinWT dimer could be isolated 
from its monomer by sequential step-wise elution of the 
heparin column with 0.6 M and 1.2 M NaCl washes, the 
latter containing purified gremlinWT uniquely in a dimeric 
form (98.5% purity as assessed by SDS-PAGE followed 
by silver staining of the gel) (Figure 1F). Of note, the 
13.4 kDa gremlin breakdown product was absent in our 
preparation after heparin chromatography (Figure 1E–1F).
Gremlin forms covalently bound homodimers 
through Cys141
In silico studies predicted that gremlin may 
form covalent homodimers through a Cys141-Cys141 
disulfide bridge [21]. This hypothesis is supported by 
the observed effect of the intracellular redox state on 
the dimer-to-monomer ratio of the released protein (see 
above) and with the absence of the corresponding Cys 
residue in monomeric SOST [20] (Figure 2A). On this 
basis, RosettaDock software [26] was applied for in silico 
docking of two gremlin monomers whose conformation 
was obtained by homology modelling using the NMR 
structure of SOST as a template (ModBase: 4E2EED073
1DA83D06F0DFD6B8C55B387) [20]. Among the 10 top 
scoring models generated by RosettaDock software, the 
model shown in Figure 2B (model ID: 0267; total score: 
-29.594; interface score -4.429; interchain contact -20) 
shows that Cys141 residues are located at the interface 
between the two monomers at a distance compatible with 
an intermolecular disulfide bridge.
To assess this hypothesis, we generated a recombinant 
gremlin mutant in which Cys141 was replaced by an Ala 
residue (gremlinC141A). Similar to gremlinWT, his-tagged 
gremlinC141A was expressed and purified from HEK293T 
cell supernatant by sequential IMAC and heparin 
affinity chromatography (85.9% purity). As anticipated, 
gremlinC141A does not form covalent homodimers, only 
23-27 kDa immunoreactive bands being detectable after 
SDS-PAGE under non-reducing conditions (Figure 2C). 
Similarly to gremlinWT monomer, gremlinC141A binds to the 
heparin column with an affinity lower than gremlinWT dimer, 
eluting from the column at 0.6-0.7 M NaCl (Figure 2D). 
Moreover glutaraldehyde treatment rules out the possibility 
that gremlinC141A may form non covalent dimers (Figure 2E), 
while confirming that gremlinWT exists in a dimeric form.
Monomeric gremlinC141A retains its BMP 
antagonist activity
BMP antagonists bind to and sequester BMPs in 
inactive complexes, preventing their interaction with 
cognate receptors and the transcription of various BMP-
dependent genes, including hepcidin [27]. On this basis, 
to assess how gremlin oligomerization might affect its 
BMP antagonist activity, purified gremlinWT dimer and 
gremlinC141A monomer were evaluated for their capacity 
to inhibit the BMP4-dependent up-regulation of the 
luciferase reporter gene driven by the BMP-responsive 
Figure 1: Gremlin exists both as a monomer and a covalent dimer. A. total lysates from healthy murine organs were 
immunoprecipitated with anti-gremlin antibody, separated by SDS-PAGE under non-reducing conditions and probed with anti-gremlin 
antibody. Black arrow, gremlin dimer; open arrow, gremlin monomer. IgG were used as a control. B. FGF2-T-MAE cells were treated with 
increasing concentrations of H2O2 for 1 hour. At the end of incubation, the cells were incubated for 4 hours with fresh medium. Conditioned 
medium was collected and immunoprecipitated with anti-gremlin antibody. Immunoprecipitated fractions were analysed by WB under non-
reducing conditions. C-D. recombinant his-tagged gremlinWT was transiently expressed in HEK293T cells, purified by IMAC and analyzed 
by SDS-PAGE followed by Western blotting (WB) under non-reducing (C) or by analytical size exclusion chromatography. The elution 
profile of gremlin was obtained by dot blot analysis of the eluted fractions (D). Black arrows indicate the retention volume of standard 
proteins (seroalbumin: 132 and 66 kDa; ovalbumin: 45 kDa; carbonic anhydrase: 29 kDa and lactoalbumin: 14.2 kDa). E. IMAC purified 
gremlin was further subjected to heparin-affinity chromatography. Heparin column was washed with a discontinuous NaCl gradient. Eluted 
fractions were separated by SDS-PAGE under non-reducing conditions and probed with anti-gremlin antibody. Black arrow, gremlin dimer; 
open arrow, gremlin monomer. F. pure dimeric gremlinWT was analysed by SDS-PAGE followed by Western blotting (WB) under non-
reducing (-βME) and reducing (+βME) conditions and by silver staining (SS) of the gel.
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hepcidin promoter in HepG2 cells [27]. As shown in 
Figure 3A, the two proteins inhibit BMP4 activity with 
similar potency, with ID
50
 values equal to 40 and 80 ng/
mL, respectively. Accordingly, dose-response ELISA 
experiments demonstrated that gremlinWT dimer and 
gremlinC141A monomer bind immobilized BMP4 with a 
similar capacity (Figure 3B), thus confirming the presence 
of similar amounts of active molecules per unit mass in the 
two protein preparations.
BMPs control dorso-ventral symmetry during 
embryonic development and the overexpression of 
BMP antagonists results in dorsalized embryos [28]. In 
order to further assess the effect of oligomerization on 
the BMP antagonist activity of gremlin, gremlinWT and 
gremlinC141A mRNAs were injected at the 1-4 cell stage 
in zebrafish embryos and their effect on dorsalization was 
assessed at 24 hours after injection. As shown in Figure 
3C, embryos were scored as normally developed embryos 
or according to the severity of their dorsalization defects: 
“mild phenotype” embryos showed a smaller posterior 
trunk with a curly tail and shortened yolk extension; 
“severe phenotype” embryos had visible head structures, 
but curly trunk and tail; “very severe phenotype” embryos 
had undistinguishable tissue structures sitting on the yolk 
ball and could not be de-chorionated. Increasing doses of 
gremlinWT and gremlinC141A mRNAs produced comparable 
dorsalization outcomes, confirming their similar BMP 
antagonist effects (Figure 3D).
Figure 2: Gremlin forms disulfide-bound homodimers through Cys141. A. CLUSTAL W sequence alignment of the cystine-
knot domain of gremlin and of structurally related SOST. B. surface view of the predicted structure of gremlin homodimer generated by 
docking simulation with RosettaDock software (model 0267; total score: -29.594; interface score -4.429; interchain contact -20). Gremlin 
homodimer subunits are in red or light blue. Cys141 residues are in yellow and orange spheres. The previously identified BMP4-binding 
region of gremlin is depicted in green. C. gremlinC141A mutant was transiently expressed in HEK293T cells and sequentially purified from 
cell supernatant by IMAC and heparin-affinity chromatography. Heparin column was eluted with a discontinuous NaCl gradient. Eluted 
fractions were separated by SDS-PAGE under non-reducing conditions and probed with anti-gremlin antibody. D. purified gremlinC141A 
monomer was analysed by WB under non-reducing and reducing conditions and by SS of the gel. E. Gremlin wt and gremlinC141A were 
incubated in the absence or in the presence of 0.05% glutaraldehyde for 20 minutes at RT, separated by SDS-PAGE under reducing 
conditions and probed with anti-gremlin antibody.
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Monomeric gremlinC141A is devoid of 
pro-angiogenic activity
Gremlin is a non-canonical angiogenic VEGFR2 agonist 
[14, 15]. To assess whether monomeric gremlinC141A retains a 
significant pro-angiogenic activity, we evaluated its capacity to 
activate VEGFR2 in HUVECs. Immunofluorescence, Western 
blot and ELISA analyses revealed that gremlinC141A does not 
induce a significant VEGFR2 phosphorylation when compared 
to gremlinWT (Figure 4A–4C), although the two preparations 
contain similar amounts of active molecules per unit mass, as 
indicated by their similar BMP antagonist potency. In addition, 
FACS analyses demonstrated that gremlinC141A is unable to 
induce a significant increase of total tyrosine phosphorylation 
and ROS production in both VEGFR2-overexpressing ECs 
and HUVEC when compared to gremlinWT (Figure 4D and 
4E). Accordingly, monomeric gremlinC141A fails to trigger the 
formation of endothelial sprouts from HUVEC spheroids 
embedded in fibrin gel (Figure 4F).
In keeping with the in vitro observations, gremlinC141A 
is devoid of a significant angiogenic activity in vivo in the 
chick embryo chorioallantoic membrane (CAM) assay 
(Figure 4G). Also, gremlinC141A does not induce neovessel 
formation in a murine Matrigel plug assay, as assessed by 
immunofluorescence analysis using anti CD31 antibodies 
(Figure 4H) and by RT-qPCR analysis of cd31 mRNA levels 
in the plugs (Figure 4I). At variance, dimeric gremlinWT 
induces angiogenic responses in all these assays.
Monomeric gremlinC141A exerts a non-productive 
interaction with VEGFR2
Surface plasmon resonance (SPR) analysis had 
shown that gremlin and VEGF-A
165
 bind the extracellular 
domain (ECD) of VEGFR2 with similar affinities [29]. On 
this basis, we assessed the capacity of gremlinC141A to bind 
ECD-VEGFR2 immobilized to a BIAcore sensorchip. 
Surprisingly, monomeric gremlinC141A and dimeric 
gremlinWT bind ECD-VEGFR2 with the same affinity 
(Kd = 73 ± 35 nM and 73 ± 15 nM, respectively) (Figure 
5A). In keeping with SPR results, the two proteins equally 
bind to high affinity sites on the cell surface of VEGFR2-
overexpressing ECs, as assessed by ELISA (Figure 5B). Of 
note, gremlin binding is totally competed by VEGF-A
165
. 
Moreover, FRET analysis performed on HEK293T cells 
co-transfected with CFP-tagged and YFP-tagged ECD-
VEGFR2 showed the formation of CFP-ECD-VEGFR2/
YFP-ECD-VEGFR2 complexes upon stimulation with 
gremlinWT dimer but not with gremlinC141A monomer 
(Figure 5C). In addition, cell surface biotinylation analysis 
demonstrated that, at variance with gremlinWT, gremlinC141A 
does not induce VEGFR2 internalization in HUVECs 
(Figure 5D). Taken together, our data demonstrate that 
monomeric gremlinC141A can bind VEGFR2, but is devoid 
of the capacity to induce receptor dimerization and 
internalization, leading to a non-productive interaction 
with the receptor.
Figure 3: GremlinC141A retains its BMP-antagonist activity. A. HepG2 cells were transiently transfected with a construct 
harbouring BMP-responsive hepcidin promoter upstream to the luciferase reporter gene. Serum-starved transfected cells were then 
stimulated with 50 ng/mL of BMP4 in the absence or the presence of increasing amounts of either gremlinWT (●) or gremlinC141A (▼). 
After 16 hours incubation, cells were lysed, and luciferase activity was measured. Data are expressed as percent of luciferase activity 
measured in BMP4 stimulated cells and are the mean ± SEM of 3 independent experiments. Two-Way ANOVA followed by Bonferroni’s 
test revealed that the dose-response curves of the two proteins were not statistically different. B. 96-well plates coated with 250 ng/mL of 
BMP4 were incubated with increasing concentrations of gremlinWT or gremlinC141A. Then, the capacity of gremlinWT (●) or gremlinC141A (▼) 
to bind to immobilized BMP4 was assessed by ELISA assay using an anti-gremlin antibody. C-D. zebrafish embryos were injected (at 1-4 
cell stage) with the indicated doses of either gremlinWT or gremlinC141A mRNA. Representative dorsalized embryo phenotypes at 24 hours 
after injection (C). All embryos were viewed laterally. D, percentage of embryos in different categories at 24 hours after injection. Data 
are the mean ± SEM of 3 independent experiments. *, p<0.05; **, p<0.01, One-Way ANOVA followed by Bonferroni’s test versus control.
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Monomeric gremlin is a VEGFR2 antagonist
To assess whether gremlinC141A may act as a 
VEGFR2 antagonist, we evaluated the capacity of 
gremlinC141A to affect the pro-angiogenic of activity of 
VEGF-A
165
. To this purpose, HUVECs were treated with 
VEGF-A
165
 in the absence or in the presence of increasing 
concentrations of gremlinC141A. Monomeric gremlinC141A 
inhibits VEGFR2 phosphorylation and the sprouting of 
HUVEC spheroids triggered by VEGF-A
165
 in a dose-
dependent manner (Figure 6A–6B). Under the same 




To evaluate whether gremlinC141A may hamper the 
angiogenic potential of VEGF-A
165
 also in vivo, Matrigel 
plugs containing 400 ng of VEGF-A
165
 were injected 
subcutaneously in mice in the absence or in the presence 
of 2.0 μg of gremlinC141A. Matrigel containing PBS or 
gremlinC141A alone were used as controls. In keeping with 
the in vitro results, gremlinC141A significantly reduces the 
angiogenic activity of VEGF-A
165
 also in vivo, as assessed 
by immunofluorescence analysis using anti CD31 antibodies 
and RT-qPCR analysis of cd31 mRNA levels in the plugs 
(Figure 6C–6D). Taken together, our results show that 
gremlinC141A abrogates the angiogenic activity of VEGF-A
165
 
by acting as a VEGFR2 antagonist. To evaluate whether this 
capacity is limited to the monomeric gremlinC141A mutant 
or it is shared also by the gremlinWT monomer, gremlinWT 
dimer and a mixture containing equivalent amounts of 
monomeric and dimeric gremlinWT were assessed for their 
Figure 4: Monomeric gremlinC141A is devoid of pro-angiogenic activity. A-C. serum-starved HUVECs were treated for 5 minutes 
with 100 ng/mL (or the indicated dose) of gremlinWT or gremlinC141A. Treated cells were then immunostained with anti-phospho-VEGFR2 (Y1175) 
antibody followed by Alexa Fluor 488 secondary antibody and nuclear counterstaining with DAPI (scale bar, 10 μm) (A) or by HRP secondary 
antibody (B). Uniform loading of the gels was confirmed by incubation of the membranes with anti-VEGFR2 antibodies. Alternatively, the capacity 
of gremlinWT (black bars) or gremlinC141A (open bars) to induce VEGFR2 phosphorylation was assessed by ELISA assay, using anti-pVEGFR2 
(Y951) antibody (C). Data are the mean ± SEM of 3 independent experiments. D. VEGFR2-overexpressing ECs were stimulated for 10 minutes 
with 20 ng/mL of gremlinWT (red line) or gremlinC141A (blue line) and assessed by FACS analysis for total tyrosine phosphorylation using an anti-
phospho-Tyr antibody. E. FACS analysis of ROS production was carried out on HUVEC pre-loaded with 5 μM DCFH-DA and stimulated for 
10 minutes with 10 ng/mL of gremlinWT (red line) or gremlinC141A (blue line). Representative mean fluorescence intensity histograms are shown. 
F. HUVEC spheroids, embedded in fibrin gel, were stimulated with increasing concentrations of gremlinWT (●) or gremlinC141A (▼). After 24 hours EC 
sprouts were counted. Data are the mean ± SEM of the number of sprouts/spheroid measured in 50 spheroids. G. alginate implants containing 60-120 
ng of gremlinWT (black bars) or gremlinC141A (open bars) were grafted onto chicken embryo CAMs. After 72 hours, neovessels converging towards 
the implant were counted. Data are expressed as mean ± SEM (n=10). H-I. liquid Matrigel was mixed with 1.0 μg/mL gremlinWT or gremlinC141A 
and injected subcutaneously into the flank of C57BL/6 mice. Matrigel with PBS alone was used as negative control. One week after injection, plugs 
were harvested and CD31+ endothelial cells were examinated by immunofluorescence (H, scale bar, 10 μm) and cd31 mRNA expression levels were 
measured by RT-qPCR analysis (I). Data are the mean ± SEM (n=10-15) and are expressed as relative expression ratios (ΔΔCt– Fold increase) using 
one PBS plug as reference. *, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.001, One-Way ANOVA followed by Bonferroni’s test versus control.
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Figure 5: Monomeric gremlinC141A exerts a non-productive interaction with VEGFR2. A. increasing concentrations of gremlinWT or 
gremlinC141A were injected on ECD-VEGFR2-coated CM5 sensorchips. Response units (RU) were recorded as a function of time. For each concentration 
of the ligand, the SPR response at equilibrium was used to build the normalized dose-response binding isotherms of gremlinWT (●) and gremlinC141A (▼) 
with ECD-VEGFR2. Data are the mean ± SEM of 2 independent experiments. The continuous and dashed lines are the Langmuir fits for the data points 
of gremlinWT and gremlinC141A respectively. B. VEGFR2-overexpressing ECs were incubated with 150 ng/mL of gremlinWT (black bar) or gremlinC141A 
(open bar) in the absence or presence of 1.5 μg of VEGF-A
165
 for 2 hours at 4°C. Cells were then washed with 2.0 M NaCl to remove gremlin bound to 
HSPGs and gremlin bound to cell-surface VEGFR2 was revealed by ELISA using anti-gremlin antibody. Data are the mean ± SEM of 3 independent 
experiments. C. HEK293T cells were transiently co-transfected with CFP-tagged and YFP-tagged ECD-VEGFR2 and stimulated with 100 ng/mL of 
gremlinWT (black bars) or gremlinC141A (open bars) for 10 minutes. Cells were then analysed for FRET efficiency by acceptor photo-bleaching. FRET 
efficiency was calculated using the formula: FRET = (Dpost - Dpre)/Dpost, where Dpost and Dpre represent the donor (ECFP) emission intensities before 
and after photo bleaching, respectively. Representative pictures of FRET efficiency are shown in right panels, where dots correspond to FRET events 
(rainbow colour: range 0-20 FRET efficiency). Data are the mean ± SEM (n=20). D. HUVECs were stimulated with 100 ng/mL of gremlinWT (black 
bars) or gremlinC141A (open bars) for 15 minutes at room temperature. Cell-surface proteins were then labelled with biotin 3-sulfo-N-hydroxysuccinimide 
ester sodium salt. Cell lysates were immunoprecipitated with anti-VEGFR2 antibody, separated by SDS-PAGE and probed with HRP-streptavidin to 
visualize biotinylated VEGFR2 (upper panel). Densitometric analyses were performed on blots obtained from 3 independent experiments and data are 
expressed as % of control (bottom panel). *, p<0.05; *** p<0.005, One-Way ANOVA followed by Bonferroni’s test versus control.
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Figure 6: GremlinC141A is a VEGFR2 antagonist. A. serum-starved HUVECs were stimulated with 5 ng/mL of VEGF-A
165
 for 
10 minutes in the absence or the presence of increasing concentrations of gremlinWT (●) or gremlinC141A (▼). pVEGFR2 (Y951) levels were 
then assessed by ELISA. Data are the mean ± SEM of 3 independent experiments. GremlinWT (o) or gremlinC141A (▽) alone were used as 
controls. VEGFR2 phosphorylation was confirmed by WB analysis using anti-pVEGFR2 (Y1175) antibody (inset). B. HUVEC spheroids, 
embedded in fibrin gel, were stimulated with 10 ng/mL of human VEGF-A
165
 in the presence of increasing concentrations of gremlinWT (●) 
or gremlinC141A (▼). GremlinWT  (o) or gremlinC141A (▽) alone were used as controls. After 24 hours, EC sprouts were counted. Data are the 
mean ± SEM of the number of sprouts/spheroid measured in 50 spheroids. C-D. VEGF-A
165
 (1.0 μg/mL) was mixed with liquid Matrigel 
in the absence (black bar) or the presence of gremlinC141A (5.0 μg/mL, grey bar) and injected subcutaneously in the flank of C57BL/6 mice. 
Plugs containing PBS or gremlinC141A (open bar) alone were used as controls. One week after injection, plugs were harvested and CD31+ 
endothelial cells were examinated by immunofluorescence (C, scale bar, 10 μm) and cd31 mRNA expression levels were measured by 
RT-qPCR analysis (D). E-F. Liquid Matrigel was mixed with 400 ng/mL of monomeric gremlinWT (open bar) or dimeric gremlinWT (black 
bar) or with 800 ng/mL of a sample containing both gremlinWT monomer and dimer (relative amounts: 46% and 54%, respectively; grey 
bar). Then, plugs were injected subcutaneously into the flank of C57BL/6 mice. Plugs containing PBS were used as controls. One week 
after injection plugs were harvested and and CD31+ endothelial cells were examinated by immunofluorescence (E, scale bar, 10 μm) and 
cd31 mRNA expression levels were measured by RT-qPCR (F). *, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.001, One-Way ANOVA 
followed by Bonferroni’s test versus control.
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angiogenic activity in the Matrigel plug assay. Similar to 
monomeric gremlinC141A, monomeric gremlinWT is devoid of 
a significant pro-angiogenic capacity and fully abolishes the 
angiogenic activity of dimeric gremlinWT (Figure 6E–6F).
Monomeric gremlin inhibits tumor growth and 
angiogenesis
The activation of VEGFR2 signalling represents 
a hallmark of tumor angiogenesis. Indeed, inhibitors 
targeting the VEGF-A/VEGFR2 axis strongly hamper 
tumor neovascularization and are part of numerous 
therapeutic protocols for the treatment of cancer patients 
[30, 31]. In order to assess the effect of monomeric 
gremlinC141A on tumor angiogenesis, murine VEGF-
dependent breast cancer EO771 cells [32, 33] were stably 
transfected with gremlinWT or gremlinC141A cDNAs and 
injected orthotopically in syngeneic C57BL/6 female 
mice. Tumor growth was followed for up to 17 days and 
then tumors were harvested and processed for RT-qPCR 
and immunofluorescence analyses. As shown in Figure 
7A and B, gremlinC141A overexpression caused a significant 
inhibition of tumor growth compared with mock tumors. 
Of note, gremlinWT and gremlinC141A overexpression did not 
alter the tumor expression levels of vegf and vegfr2, as 
assessed by qPCR analysis of harvested grafts (Figure 7E). 
In addition, as observed for EO771-derived tumors treated 
with the VEGFR tyrosine kinase inhibitor SU112248 [33], 
gremlinC141A overexpression efficiently inhibited tumor 
neovascularization, as demonstrated by the reduction of 
ve-cadherin mRNA levels and CD31+ area in gremlinC141A-
EO771 tumors when compared to mock lesions (Figure 
7C–7E). At variance, gremlinWT-overexpression increased 
the neovascularization of gremlinWT-lesions.
Figure 7: GremlinC141A reduces the tumorigenic and angiogenic potential of EO771 cells. A. 5×105 mock (■)- or gremlinWT 
(●)- or gremlinC141A -EO771 (▼) cells were injected orthotopically in 15-week-old female mice (6 mice/group). Tumor growth was followed 
for up to 17 days. Tumor volume (in mm3) is expressed as a function of time. In the inset the PCR analysis for exogenous rat gremlin 
mRNA in tumor samples is shown. At the end of experiments tumors were harvested, weighed B and analysed by immunofluorescence 
using anti CD31 antibodies (red). Nuclei were counterstained with DAPI (blue) (scale bar 100 μm) C. D. CD31+ area was quantified and 
normalized to area (3-5 fields per tumor). Data are the mean ± SEM. E. murine vegf, vegfr2 and ve-cadherin (ve-cad) mRNA expression 
levels were measured by RT-qPCR. Data were normalized on murine gapdh and are expressed as fold increase vs mock tumors. F. 4×106 
mock (■)- or gremlinC141A TRAMP-C2 (▼) cells were injected subcutaneously in 15-week-old male mice (6 mice/group). Tumor growth 
was followed for up to 40 days. Tumor volume (in mm3) is expressed as a function of time. In the inset the PCR analysis for exogenous rat 
gremlin mRNA in tumor samples is shown. At the end of experiments tumors were harvested, weighed G and vessel density was analysed 
by immunofluorescence using anti CD31 antibodies H. CD31+ area was quantified and normalized to area (3-5 fields per tumor). Data are 
the mean ± SEM I. *, p<0.05; ***, p<0.005, One-Way ANOVA followed by Bonferroni’s test versus control.
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In keeping with these observations, gremlinC141A 
overexpression inhibits the growth and vascularization 
of tumors induced by murine prostate adenocarcinoma 
TRAMP-C2 cells [34] injected subcutaneously in 
syngeneic C57BL/6 male mice (Figure 7F–7I). Together, 
these data indicate that monomeric gremlinC141A inhibits 
the growth and vascularization of VEGF-dependent 
tumors by acting as a VEGFR2-antagonist.
DISCUSSION
Accumulating evidences indicate that gremlin is a 
multifunctional protein involved in several physiological 
and pathological processes, including embryonic 
development, neurodegeneration, inflammation and 
angiogenesis [35–37]. Gremlin is a member of the TGF-β 
superfamily, initially characterized as a BMP antagonist. 
BMP antagonists are expressed as covalently linked 
homodimers [like activin [4], noggin [5] and BMPs [21]], 
highly stable non-covalent homodimers [PRDC [22]] or 
monomers [follistatin [4] and SOST [20]]. Gremlin also 
elicits potent BMP-independent angiogenic responses 
by acting as a non-canonical VEGFR2 ligand [15]. At 
variance with BMP antagonists, VEGFR ligands need to 
be in a dimeric form in order to fully activate their cognate 
receptors and exert their pro-angiogenic function [38]. 
The presence of multiple oligomeric states is occasionally 
found among TK receptor ligands [39], including 
VEGFR ligands [40–43], and represents a mechanism 
of modulation of their activity. Unique among BMP-
antagonists, here we show that gremlin exists both as a 
monomer and as a covalent homodimer in a monomer/
dimer equilibrium in vitro and in vivo.
In silico docking predicted that amino acid residue 
Cys141 may mediate gremlin homodimerization via the 
formation of a disulfide bond between two protomers. In 
our model, which differs from the recently proposed head-
to-tail homology model of gremlin homodimer based on 
PRDC structure [19], gremlin protomers dimerize with a 
head-to-head orientation, forming a “clamp-shaped” dimer 
with two extended “clip” segments, similar to noggin [5]. 
In keeping with the structure of noggin/BMP7 complex 
[5], our model shows that the previously identified BMP-
binding motif, corresponding to amino acid sequence 
gremlin (145-174) [23], spans along the “clip” segments, 
being available for BMP binding. Site-directed Cys141-to-
Ala mutagenesis originated the gremlinC141A mutant that, at 
variance with gremlinWT, is secreted only in a monomeric 
form. Taken together, our results unequivocally 
demonstrate for the first time the covalent nature of 
gremlin homodimers, unravelling the key role of Cys141 
in the covalent homodimerization of gremlin protomers.
The molecular bases of the interaction of BMP 
antagonists with their ligands are poorly understood. As 
anticipated, BMP antagonists exists both in monomeric 
and dimeric states [5, 20]. Thus, the activity of BMP 
antagonists does not appear to be strictly dependent on 
their covalent dimerization. Here we show that gremlin 
can function as a BMP antagonist both in a monomeric and 
dimeric state, gremlinC141A monomer and gremlinWT dimer 
being equally effective in binding BMP4 and inhibiting 
BMP-mediated biological responses in vitro and in 
zebrafish embryos. It must be pointed out that the capacity 
of gremlinC141A to bind BMP4 with an affinity similar to 
gremlinWT indicates that the lack of homodimerization 
cannot be the mere consequence of significant alterations 
of the conformation of the mutagenized protein.
Productive binding to VEGFRs requires the ligand 
to be in a dimeric state. Indeed, VEGF-A, VEGF-B 
and PlGF are all active as disulfide-linked homodimers 
[38] and VEGF-C and VEGF-D exist in a monomer/
dimer equilibrium [40–43], variants with enhanced 
dimer stability showing a stronger activity. Also, 
recombinant VEGF heterodimers, in which only one of 
the two protomers retains a receptor binding capacity, 
exert a potent antagonist activity by preventing VEGFR 
dimerization [44, 45]. Here we show that monomeric 
gremlinC141A binds VEGFR2 with the same affinity 
as dimeric gremlinWT. However, the interaction is not 
productive and fails to trigger receptor dimerization and 
internalization. Accordingly, gremlinC141A is unable to elicit 
VEGFR2-dependent angiogenic responses in vitro and 
in vivo.
Similar to monomeric VEGF [46], gremlinC141A 
monomer prevents the angiogenic activity of VEGF-A 
as well as of gremlinWT dimer, acting as a VEGFR2 
antagonist. The VEGFR2-antagonist capacity of 
monomeric gremlinC141A results in the reduction of 
tumor growth and vascularization in breast carcinoma 
and prostatic cancer models. Therefore, our data show 
that gremlin monomer has unique biological properties 
that allow for the first time the dissociation of the BMP 
antagonist activity of gremlin from its VEGFR2-dependent 
functions, representing a valuable tool for the elucidation 
of gremlin biology in physiological and pathological 
settings.
Here we provide evidences that the modulation 
of the oligomeric state of gremlin allows to separate the 
receptor binding activity of gremlin from its VEGFR2 
dimerization activity, thus enabling the design of receptor 
antagonists. Because aberrant VEGFR2 signalling is 
associated with tumor neovascularization, targeting 
VEGFR2 activation has become an intense area of anti-
cancer research. The mutated monomeric variant of 
gremlin described in this report may provide the basis for 
the development of new VEGFR2-specific strategies to 
inhibit pathological angiogenesis.
Gremlin is expressed in several tumors by stromal 
and parenchymal cells, including activated endothelial 
cells [12, 14, 47]. BMPs elicit effects that can be 
either detrimental or beneficial for tumor growth and 
progression [2]. In addition, BMPs induce endothelial 
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cell proliferation and migration in vitro and angiogenesis 
in vivo [3, 48]. Thus, gremlin and other extracellular 
BMP antagonists have been alternatively considered 
tumor promoting or oncosuppressive factors. To this 
regard, it must be pointed out that monomeric wild-
type gremlin recapitulates the antagonistic activity 
of the monomeric gremlinC141A mutant. This suggests 
that tuning of the monomer/dimer equilibrium may 
modulate VEGFR2 activation or inhibition by gremlin, 
the oligomerization state of the protein representing a 
possible post-translational mechanism of control of the 
activity of the highly angiogenic dimer in physiological 
and pathological conditions, including cancer. In keeping 
with this hypothesis, our data demonstrate that the redox 
status of the cell affects gremlin dimerization, as observed 
for VEGF-C [42] and VEGF-D [43]. Thus, the redox 
microenvironment may modulate the monomer/dimer 
equilibrium of gremlin during tumor growth, resulting 
in either a pro- or anti-angiogenic phenotype because of 
the balance between the VEGFR2 agonist and antagonist 
activity of the protein. Accordingly, our data show that 
gremlinWT overexpression results in a further increase of 
blood vessel density in VEGF-dependent EO771 tumor 
grafts, whereas overexpression of the monomeric mutant 
causes a significant decrease of tumor vascularization and 
growth.
In conclusion, we demonstrate that gremlin 
functions both as a monomer and as a covalent homodimer 
and that dimerization is strictly required for the pro-
angiogenic activity of gremlin, being dispensable for 
its BMP antagonist activity. In addition, we show that 
monomeric gremlin is a potent VEGFR2 antagonist 
endowed with anti-angiogenic, anti-tumor functions. Our 
findings provide new insights into the molecular bases of 
gremlin dimerization with significant consequences for its 
biological activity. Monomeric gremlinC141A represents as 
a novel VEGFR2 antagonist that deserves further attention 




Human embryonic kidney HEK 293T/17 (ATCC) 
cells, human hepatocellular carcinoma HepG2 (ATCC) 
cells, fetal bovine aortic endothelial GM7373 cells 
[49], FGF2-T-MAE cells [14] and murine breast cancer 
EO771 cells (kindly provided by R.Giavazzi, Mario 
Negri, Italy) were grown in Dulbecco modified Eagle’s 
medium (DMEM, Gibco Life Technologies) containing 
10% fetal calf serum (FCS, Gibco). Murine prostate 
adenocarcinoma TRAMP-C2 cells, obtained from ATCC-
LGC Standards Repository (ATCC No CRL-2731) were 
grown in maintained in DMEM supplemented with 10% 
heat inactivated FCS, 10 mM HEPES Buffer, 0.5 mM 
2-mercaptoethanol, 2.0 mM glutamine, 5 mg/L bovine 
insulin (Sigma-Aldrich) and 10 nM DHT. GM7373 cells 
were stably transfected with pcDNA3.1 vector (Invitrogen 
Life Technologies), harbouring mouse VEGFR2 cDNA 
to generate VEGFR2-overexpressing ECs. EO771 and 
TRAMP-C2 cells were stably transfected with empty 
pcDNA3 vector or pcDNA3 plasmid harbouring rat 
gremlinWT or mutant gremlinC141A. Human umbilical vein 
endothelial cells (HUVECs) were grown in M199 medium 
(Gibco Life Technologies) supplemented with 20% fetal 
calf serum (FCS, Gibco Life Technologies), endothelial 
cell growth factor (100 μg/ml) (Sigma Chemical Co., St. 
Louis, MO) and porcine heparin (Sigma) (100 μg/ml). 
HUVECs were used at early passages (I-IV) and grown 
on plastic surface coated with porcine gelatin (Sigma).
Generation of DNA constructs
The cDNA sequence of rat gremlinWT was amplified 
from pMEX-rGremlin (NM_019282.3) [provided by L. 
Topol [50]] and cloned in pcDNA3 vector (Invitrogen) 
upstream to His-Tag sequence to obtain pcDNA3-rGremlin-
HisTagWT. Mutagenesis of Cys141-to-Ala was carried out 
using the QuikChange Lightning Site-directed Mutagenesis 
Kit (Agilent Technologies). Primers forward 5′-CCTTTCA
GTCCGCCTCCTTCTGCAAGCCC-3′ and reverse 5′-CT
TGCAGAAGGAGGCGGACTGAAAGGAACC-3′ were 
used to obtain pcDNA3-rGremlin-HisTagC141A.
Recombinant gremlin expression and 
purification
His-tagged recombinant gremlinWT and gremlinC141A 
were transiently expressed in HEK293T cells. HEK293T 
cells were transfected using polyethylenimine (PEI, 
Polysciences, Inc.) in DMEM supplemented with 0.5% 
FCS. 12 hours after transfection, the medium was collected, 
clarified and dialysed against 5.0 L of 20 mM phosphate 
buffer (pH 8.0) containing 0.5 M NaCl (binding buffer). 
Gremlin was purified from the dialysed medium by 
IMAC on 1.0 mL HiTrap Chelating HP Ni2+-column (GE 
Healthcare), pre-equilibrated with binding buffer, using 
AKTA™ start FPLC system (GE Healthcare). The column 
was eluted with a discontinuous imidazole gradient (10, 
40 and 250 mM), gremlin eluting at 250 mM imidazole. 
Partially purified gremlin was buffer exchanged with PBS 
and subjected to heparin-affinity chromatography. To 
this purpose, IMAC purified gremlin was loaded onto an 
heparin-Sepharose column, which was then eluted with a 
discontinuous NaCl gradient (0.3-1.2 M NaCl). Fractions 
of interest were collected and buffer exchanged with PBS.
For preparative gremlin purification, the heparin 
column was washed with PBS containing 0.6/0.5 M NaCl 
and then eluted with PBS containing 1.2 M NaCl. Finally, 
purified gremlin was buffer exchanged with PBS. Proteins 
were quantified by measuring the OD at 280 nm.
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Size exclusion chromatography
IMAC purified gremlin resuspended in 0.15 M 
sodium sulphate was loaded onto a pre-equilibrated 
TSK3000 PWXL column with pre-column (Tosoh 
Bioscieces) and subjected to 0.5 mL/min size exclusion 
chromatography [isocratic HPLC-GPC system (Jasko)]. 
Eluted fractions (0.1 mL) were collected and analysed 
by dot blotting using an anti-gremlin antibody (R&D 
system). Standard proteins (seroalbumin: 132 and 66 
kDa; ovalbumin: 45 kDa; carbonic anhydrase: 29 kDa and 
lactoalbumin: 14,2 kDa) were used to build the calibration 
curve.
Western blotting and gremlin 
immunoprecipitation
Samples were separated by SDS-PAGE performed 
under reducing [+2-MercaptoEthanol (βME)] or non-
reducing (-βME) conditions. Gels were then alternatively 
stained by silver staining or processed for Western blot 
(WB) analyses with polyclonal rabbit anti-gremlin (R&D). 
WB/dot blot densitometry was performed with ImageJ 
software. For gremlin immunoprecipitation, organs 
were explanted from healthy C57BL/6 mice, lysed and 
immunoprecipitated with polyclonal goat anti-gremlin 
(R&D). When indicated gremlinWT or gremlinC141A 
were incubated in the absence or in the presence of 
0.05% glutaraldehyde for 20 minutes at RT, separated by 
SDS-PAGE under reducing conditions and probed with 
polyclonal rabbit anti-gremlin.
In silico docking study for gremlin homodimeric 
complex
Sequence alignments were obtained using 
CLUSTAL W software [51]. The docking software 
RosettaDock was used to evaluate the possible orientation 
and conformation of gremlin homodimers [26, 52]. We 
used as input the human monomeric gremlin protein 
structure model reshaped from the 3D structure of SOST 
[20]. Then, an educated guess regarding the starting 
position of the two monomers was uploaded in the 
RosettaDock query form. In this well validated approach, 
the algorithm identifies low-energy conformations 
of a protein-protein interaction near a given starting 
configuration by optimizing rigid-body orientation and 
side-chain conformations as described in [26, 52].
Luciferase reporter gene assay
HepG2 cells were transiently transfected with 
pGL2-Luc-HAMP vector harbouring BMP-responsive 
hepcidin promoter upstream to Firefly luciferase 
reporter gene (kindly provided by M. Poli, Molecular 
Biology Laboratory, DMMT, University of Brescia), in 
combination with pRL-TK Renilla Luciferase vector 
(Promega) as a control for uniform lysate analyses. 
12 hours after transfection, serum-starved cells were 
stimulated with 50 ng/mL of BMP4 (R&D) for 16 hours in 
the absence or in the presence of increasing concentrations 
of gremlinWT or gremlinC141A. Cells were then lysed and 
luciferase activity was determined with the Dual Reporter 
Assay kit (Promega). Relative luciferase activity was 
calculated as the ratio of Firefly (reporter) to Renilla 
(control) luciferase activity and is expressed as percent of 
the activity of BMP4-stimulated cells.
ELISA assays
96-well plates coated with 250 ng/mL of human 
BMP4 or seeded with VEGFR2-overexpressing ECs were 
incubated with gremlinWT or gremlinC141A in the absence 
or presence of VEGF-A
165
. Bound gremlin or pVEGFR2 
were detected by incubation with goat anti-gremlin (R&D) 
or anti-pVEGFR2 (Y951; Santa Cruz Biotechnology) 
antibody followed by secondary horseradish peroxidase 
(HRP)-conjugated antibody (Santa Cruz). Peroxidase 
substrate (KPL, Kirkegaard & Perry Laboratories, Inc.) 
was finally added to the wells and absorbance was 
measured at 405 nm.
BMP-antagonist assay in Zebrafish
GremlinWT and gremlinC141A mRNAs were 
synthesized in vitro using the T7 mMESSAGE 
mMACHINE transcription kit (Ambion, ThermoFisher 
Scientific). 1-4 cell-stage embryos of the wild-type AB 
zebrafish line were injected with different amounts of 
mRNA and maintained in fish water at 28°C. Embryos 
were analysed at 22-24 hour post fertilization (hpf).
Intracellular signalling analyses
HUVECs or VEGFR2-overexpressing ECs were 
treated with gremlinWT or gremlinC141A, fixed and decorated 
either with anti-phospho-VEGFR2 rabbit antibody 
(Y1175, Cell Signaling Technology), followed by Alexa 
Fluor 488 anti-rabbit IgG (Invitrogen Life Technologies) 
or anti-phospho-Tyr mouse antibody (4G10, Upstate 
Biotechnology, Inc.). Cells were alternatively analysed 
using Axiovert 200M epifluorescence microscope 
equipped with Plan-Apochromat 63X/1.4 NA oil objective 
(Zeiss) or subjected to FACS analysis ( MACSQuant, 
Miltenyi Biotec) respectively. Intracellular ROS levels 
were assessed by measuring fluorescence intensity in 
HUVEC cells suspended in serum-free medium and loaded 
with the redox-sensitive dye DCFH-DA (5 μM, Molecular 
Probe, Life Technologies), as previously described [16]. 
Cells were then washed, stimulated with gremlinWT or 
gremlinC141A and finally subjected to FACS analysis. FACS 
analyses were performed with MACSQuant Analyzer 




Sprouting of HUVEC spheroids was analysed as 
described [14]. Briefly, spheroids were prepared in 20% 
methylcellulose medium, embedded in fibrin gel and 
stimulated with increasing concentrations of gremlinWT or 
gremlinC141A in the presence or the absence of VEGF-A
165
. 
The number of radially growing cell sprouts was counted 
after 24 hours using Axiovert 200M microscope equipped 
with LD A Plan 20X/0.30PH1 objective (Zeiss).
CAM assay
Alginate beads containing PBS or gremlinWT or 
gremlinC141A were placed on the CAM of fertilized white 
Leghorn chicken eggs at day 11 of incubation [16]. After 
72 hours, newly formed blood vessels converging toward 
the implant were counted at X5 magnification using a 
STEMI SR stereo-microscope equipped with an objective 
f of 100 mm with adapter ring 475070 (Zeiss).
Matrigel plug assay
All the procedures involving mice and their 
care conformed to institutional guidelines that comply 
with national and international laws and policies (EEC 
council Directive 86/609, OJ L 358, 12 December 1987). 
7-week-old C57BL/6 mice (Charles River Laboratories 
International, Inc.) were injected subcutaneously with 400 
μL of liquid Matrigel (Trevigen, Inc.) containing 400 ng 
of gremlin. For the competition assay mice were injected 
with 400 μL of liquid Matrigel containing 400 ng of 
human VEGF-A
165
 in the absence or the presence of 2 μg 
of gremlinWT or gremlinC141A. Matrigel with PBS alone was 
used as negative control. One week after injection, mice 
were sacrificed and plugs were harvested and processed 
for immunofluorescence using anti CD31 antibodies and 
RT-qPCR as previously described [53]. Matrigel slices 
were analysed using Axiovert 200M epifluorescence 
microscope equipped with Plan-Neofluar 20X/0.5 NA 
objective (Zeiss). CD31+ area was measured by ImageJ 
software analysis. The mRNA expression levels of murine 
cd31 were normalized to the levels of human gapdh. Data 
are expressed as relative expression ratios (ΔΔCt – Fold 
increase) using one PBS plug as reference.
Surface plasmon resonance (SPR) analysis
SPR measurements were performed on BIAcore 
X instrument (GE Healthcare). The extracellular domain 
D1-7 of human VEGFR2 (ECD-VEGFR2) (ReliaTech 
GmbH) was immobilized at approximately 0.036-0.064 
pmol/mm2 onto CM5 sensorchips (BIAcore). The chips 
were pre-activated with a mixture of 0.2 M N-ethyl-N′-
(3-dimethylaminopropyl)-carbodiimide hydrochloride 
and 0.05 M N-hydroxysuccinimide (35 μL; flow rate: 10 
μL/minute). After ECD-VEGFR2 immobilization (70 μL 
of a solution of 0.345 μM sVEGFR2 in 10 mM sodium 
acetate pH 4.5 at flow rate 10 μL/minute), the remaining 
dextran active moieties were deactivated with 1.0 M 
ethanolamine at pH 8.5 (35 μL, flow rate 10 μL/minute). 
The activated/deactivated dextran was used as reference. 
Increasing concentrations (from 100 ng/mL to 4 μg/mL) 
of gremlinWT or gremlinC141A were injected in HBS-EP 
buffer (BIAcore) for 10 minutes (sample volume: 50 μL; 
flow rate: 5 μL/minute; dissociation time: 2 minutes). The 
response (in response units) was monitored as a function 
of time. For each concentration of the ligand, the SPR 
response at equilibrium was used to build the normalized 
dose-response binding isotherms of gremlin with ECD-
VEGFR2. Binding isotherm points were fitted to the 
Langmuir equation for monovalent binding to determine 
equilibrium affinity constants, by using SOLAR2.0 
software (http://www.chem4tech.it/).
Fluorescence resonance energy transfer (FRET) 
analysis
FRET experiments were performed as previously 
described [17, 54]. Briefly, HEK293T cells, co-transfected 
with a pcDNA3 vector harbouring Enhanced Yellow 
Fluorescent Protein (EYFP)-ECD-VEGFR2 cDNA and a 
pcDNA3 vector harbouring Enhanced Cyan Fluorescent 
Protein (ECFP)-ECD-VEGFR2 cDNA, were seeded in 
8-well μ-Slides coverslips (ibidi GmbH) and stimulated 
with 100 ng/mL of gremlinWT or gremlinC141A for 10 
minutes. Then cells were fixed and subjected to FRET 
analysis. To this purpose, a region of interest was selected 
and photo-bleached by applying 100% intensity of a 
514 nm laser. FRET efficiency was calculated using the 
formula: FRET = (Dpost - Dpre)/Dpost, where Dpost and Dpre 
represent the donor (ECFP) emission intensities before 
and after photo-bleaching, respectively. FRET efficiency 
was also measured in a non-photobleached region of 
the same cell as in situ control. In all experiments, cells 
transfected with ECFP-EYFP fusion protein were used as 
FRET positive controls [55]. Pixel-pixel FRET efficiency 
by acceptor photobleaching was also calculated by 
“FRETcalc v5.0” of ImageJ Software [56].
VEGFR2 internalization assay
HUVECs surface biotinylation was performed as 
previously described [57]. Briefly, serum-starved HUVECs 
were stimulated for 15 minutes at room temperature with 
gremlinWT or gremlinC141A. Cells were then incubated for 2 
hours at 4°C with biotin-3-sulfo-N-hydroxy-succinimide 
ester sodium salt (biotin-NHS) (Sigma) dissolved in 
Hanks’ Balanced Salt Solution at 0.5 mg/mL. Biotin-NHS 
was inactivated by incubation with 50 mM Tris-HCl (pH 
7.4) containing 150 mM NaCl. Cells were then lysed, 
immunoprecipitated with anti-VEGFR2 antibody (Santa 
Cruz Biotechnology) and separated by reducing SDS-
PAGE. Analyses of the biotinylated immunocomplexes 
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were performed using HRP-conjugated streptavidin (GE 
Healthcare).
In vivo tumorigenesis assay
All the procedures involving mice and their care 
conformed to institutional guidelines as previously 
indicated. 5×105 mock- or gremlinWT- or gremlinC141A-
EO771 cells were injected orthotopically in 15-week-
old female C57BL/6 mice (6 mice/group). Alternatively 
5×105 mock- or gremlinC141A-TRAMP-C2 cells were 
injected subcutaneously in 15-week-old male C57BL/6 
mice (6 mice/group). At the end of experiment 
tumors were harvested and processed for RT-qPCR or 
immunofluorescence analysis. For RT-qPCR analyses, 
the mRNA expression levels of murine vegf, vegfr2 and 
ve-cadherin were normalized to the levels of murine 
gapdh. Data are expressed as relative expression ratios 
(ΔΔCt – Fold increase) using one mock plug as reference.
For immunofluorescence analyses, paraffin embedded 
tumors were stained with anti-CD31 antibody followed 
by incubation with Alexa Fluor 594-conjugated secondary 
antibody. Tumor slices were analysed using Axiovert 
200M epifluorescence microscope equipped with Plan-
Neofluar 20X/0.5 NA objective (Zeiss). CD31+ area was 
measured by ImageJ software analysis.
Data representation and statistical analyses
Data are expressed as mean ± SEM. Statistical 
analyses were performed using One-Way ANOVA 
followed by Bonferroni’s test or Student’s t-test. The 
indicated p value was set as statistically significant.
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